DRUGS group AstraZeneca, down 29p at 2261p, will appeal a US court ruling giving a generic drug firm the right to launch a rival to its ulcer pill Prilosec. Fears persist that its cancer drug Iressa could face fresh hurdles in the US.
Create a FREE account to continue reading
Registration is a free and easy way to support our journalism.
Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.
Thank you for registering
Please refresh the page or navigate to another page on the site to be automatically logged in